Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLAGE-VEN and RIC for Refractory AML
NCT05870995Phase 2Recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Feb 2023
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of venetoclax in acute myeloid leukemia (AML), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Disease-Free Survival at 2 years. Started Feb 2023; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05870995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05870995.